Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$125.60 USD

125.60
1,986,716

-4.93 (-3.78%)

Updated May 23, 2024 04:00 PM ET

After-Market: $125.62 +0.02 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (144 out of 249)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for DXCM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

DexCom, Inc. [DXCM]

Reports for Purchase

Showing records 261 - 280 ( 412 total )

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 261

03/15/2015

Industry Report

Pages: 10

Takeaways from DXCM and TNDM Management Meetings

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 262

02/25/2015

Company Report

Pages: 8

4Q Recap: Reiterate OUTPERFORM on Surprising Profitability and Several Exciting, Upcoming Catalysts; Raising PT to $73

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 263

02/24/2015

Company Report

Pages: 7

Q4 revenue inline, EPS ahead of street, maintain SELL

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 264

02/24/2015

Company Report

Pages: 8

CGM Project: Historical survey of 1,428 CGM users (2007 - present)

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 265

02/23/2015

Daily Note

Pages: 17

MedTech Stocks To Watch This Week

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 266

02/23/2015

Industry Report

Pages: 17

MedTech Stocks To Watch This Week

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 267

02/04/2015

Company Report

Pages: 7

Price: 24.95

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 268

01/26/2015

Daily Note

Pages: 6

FDA Allows DexCom''s CGM Data to Be Displayed on the iPhone; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 269

11/10/2014

Company Report

Pages: 9

Q3 results ahead, guidance raised, maintain SELL on valuation, PT to $37.75

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 270

11/10/2014

Company Report

Pages: 9

Q3 results ahead, guidance raised, maintain SELL on valuation, PT to $37.75

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 271

11/07/2014

Company Report

Pages: 8

3Q Results Solid Across the Board; Increasing PT to $55; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 272

11/05/2014

Company Report

Pages: 9

Historical survey of 1,357 CGM users

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 273

10/21/2014

Company Report

Pages: 7

Price: 24.95

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 274

10/20/2014

Company Report

Pages: 3

Dexcom Share Approved, Links Patients/Caregivers through iPhone/iPad Touch

Provider: The Benchmark Company

Analyst: WALD J

Price: 10.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 275

10/14/2014

Industry Report

Pages: 7

Medical Devices-Takeaways from J&J''s 3Q14 Results

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 276

09/04/2014

Company Report

Pages: 41

Choose Your Own Adventure-What is DexCom Worth?

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 100.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 277

08/08/2014

Company Report

Pages: 8

Price: 24.95

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 278

08/07/2014

Company Report

Pages: 3

Strong Second Quarter Sales, Leverage Starts to Kick In - Raising PT to $53 from $50

Provider: The Benchmark Company

Analyst: WALD J

Price: 10.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 279

08/07/2014

Company Report

Pages: 8

Q2 results ahead, guidance raised, maintain SELL on valuation, PT to $28.50

Provider: FELTL & COMPANY

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 280

08/06/2014

Company Report

Pages: 7

2Q14 Very Strong Across the Board; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party